FDA warned Absolutely Natural of Melbourne, Florida, over nonprescription drug manufacturing violations, including weak contamination investigations and component testing.
What happened
FDA inspected Absolutely Natural’s drug manufacturing facility in Melbourne, Florida, from April 22 to 24, 2025, and cited violations of current good manufacturing practice (CGMP), the rules for drug manufacturing. FDA found that the company did not adequately investigate a July 2024 batch that failed microbiological tests for total plate count and Pseudomonas aeruginosa, did not validate its rapid microbiological test methods, and did not perform required identity testing on incoming component lots. FDA reviewed the company’s May 15, 2025, response and found it inadequate.
What FDA found
The company rejected a batch that failed microbiological tests in July 2024 but did not fully investigate the cause or assess other batches that might be affected.
21 CFR 211.192The company used a rapid microbiological test system without adequately validating it for its intended use or showing it was equivalent to standard methods.
21 CFR 211.165(e)The company did not perform required identity testing on each incoming component lot, including high-risk components where testing is needed to detect hazardous impurities.
21 CFR 211.84(d)(1)
What FDA wants
FDA asks the company to respond in writing within 15 working days with the actions it has taken and will take to correct the violations and prevent recurrence. If the company cannot complete the actions in that time, it must state the reasons for delay and a completion schedule.
Who should pay attention
- brands that buy OTC drug products from this manufacturer
- other OTC drug makers using rapid microbiological methods
- suppliers and quality teams handling high-risk drug components
This is a summary. Read the original letter on fda.gov.